(Q38463184)

English

Strong correlation between results of fluorescent in situ hybridization and immunohistochemistry for the assessment of the ERBB2 (HER-2/neu) gene status in breast carcinoma

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

Strong correlation between results of fluorescent in situ hybridization and immunohistochemistry for the assessment of the ERBB2 (HER-2/neu) gene status in breast carcinoma (English)

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

immunohistochemistry

1 reference

based on heuristic

inferred from title

Erb-b2 receptor tyrosine kinase 2

1 reference

based on heuristic

inferred from title

Anne Vincent-Salomon

2

object named as

Vincent-Salomon A

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

Xavier Sastre-Garau

7

object named as

Sastre-Garau X

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

author name string

Couturier J

1

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

Nicolas A

3

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

Beuzeboc P

4

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

Mouret E

5

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

Zafrani B

6

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

publication date

1 November 2000

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

Modern Pathology

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

13

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

11

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

1238-1243

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

https://scigraph.springernature.com/pub.10.1038/modpathol.3880228

0 references

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3880228

21 January 2018

Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3880228

21 January 2018

Prognostic importance of c-erbB-2 expression in breast cancer. International (Ludwig) Breast Cancer Study Group.

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3880228

21 January 2018

HER-2/neu in node-negative breast cancer: prognostic significance of overexpression influenced by the presence of in situ carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3880228

21 January 2018

Immunohistochemical detection of HER2/neu in patients with axillary lymph node negative breast carcinoma. A study of epidemiologic risk factors, histologic features, and prognosis.

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3880228

21 January 2018

HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3880228

21 January 2018

Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3880228

21 January 2018

Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3880228

21 January 2018

Antisense oligonucleotides specific for the HER2/neu oncogene inhibit the growth of human breast carcinoma cells that overexpress HER2/neu

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3880228

21 January 2018

ERBB2 amplification in breast cancer analyzed by fluorescence in situ hybridization

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3880228

21 January 2018

c-erbB2/neu gene and chromosome 17 analysis in breast cancer by FISH on archival cytological fine-needle aspirates.

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3880228

21 January 2018

Prognostic significance of HER-2/neu oncoprotein expression in node-positive breast cancer. The influence of the pattern of immunostaining and adjuvant therapy

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3880228

7 January 2021

based on heuristic

inferred from DOI database lookup

The prognostic value of c-erbB2 in primary breast carcinomas: A study on 942 cases

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3880228

7 January 2021

based on heuristic

inferred from DOI database lookup

ERBB2 oncogene in human breast cancer and its clinical significance

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3880228

7 January 2021

based on heuristic

inferred from DOI database lookup

c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3880228

7 January 2021

based on heuristic

inferred from DOI database lookup

erbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3880228

7 January 2021

based on heuristic

inferred from DOI database lookup

No significant predictive value of c-erbB-2 or p53 expression regarding sensitivity to primary chemotherapy or radiotherapy in breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3880228

7 January 2021

based on heuristic

inferred from DOI database lookup

erbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3880228

7 January 2021

based on heuristic

inferred from DOI database lookup

ERBB2 overexpression in breast carcinomas: no positive correlation with complete pathological response to preoperative high-dose anthracycline-based chemotherapy

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3880228

7 January 2021

based on heuristic

inferred from DOI database lookup

Quantitative PCR analysis of c-erb B-2 (HER2/neu) gene amplification and comparison with p185(HER2/neu) protein expression in breast cancer drill biopsies

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3880228

7 January 2021

based on heuristic

inferred from DOI database lookup

c-erbB-2 amplification in breast cancer: detection in formalin-fixed, paraffin-embedded tissue by in situ hybridization

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3880228

7 January 2021

based on heuristic

inferred from DOI database lookup

c-erbB-2 over-expression in amplified and non-amplified breast carcinoma samples

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3880228

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparison of fluorescence in situ hybridization and immunohistochemistry for the evaluation of HER-2/neu in breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3880228

7 January 2021

based on heuristic

inferred from DOI database lookup

Detection and quantitation by fluorescence in situ hybridization (FISH) and image analysis of HER-2/neu gene amplification in breast cancer fine-needle samples

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3880228

7 January 2021

based on heuristic

inferred from DOI database lookup

Determination of Her-2/Neu status in breast carcinoma: comparative analysis of immunohistochemistry and fluorescent in situ hybridization

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3880228

7 January 2021

based on heuristic

inferred from DOI database lookup

Specificity of HercepTest in determining HER-2/neu status of breast cancers using the United States Food and Drug Administration-approved scoring system

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3880228

7 January 2021

based on heuristic

inferred from DOI database lookup

Increased HER2 with U.S. Food and Drug Administration-approved antibody

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3880228

7 January 2021

based on heuristic

inferred from DOI database lookup

Detection of DNA amplification in 17 primary breast carcinomas with homogeneously staining regions by a modified comparative genomic hybridization technique

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3880228

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1038/MODPATHOL.3880228

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

Dimensions Publication ID

0 references

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38463184&oldid=1760915305"